Gastroparesis
Gastroparesis Market

Gastroparesis, which is a translated meaning of “stomach paralysis”, is a digestive disorder characterized by delayed gastric emptying of solid food in the absence of mechanical obstruction of the stomach, resulting in the cardinal symptoms of early satiety, postprandial fullness, nausea, vomiting, belching, and bloating.


Gastroparesis Epidemiological Segmentation 

The Epidemiological Segmentation of Gastroparesis in 7MM from 2018 to 2030 is segmented as:- 


  • Total Prevalence of Gastroparesis
  • Gender-specific Prevalence of Gastroparesis
  • Severity-specific Prevalence of Gastroparesis
  • Type-specific Prevalence of Gastroparesis
  • Total Diagnosed Prevalent Population of Gastroparesis


Gastroparesis Epidemiology 

  • The total prevalent population of Gastroparesis in 7MM in 2020 was approximately 34.2 million 
  • Among the 7MM, the highest prevalent cases of Gastroparesis were observed in the US i.e., 13.3 million in 2020
  • The total prevalent population of Gastroparesis in Japan in 2020 was approximately 5.8 million


Gastroparesis Market

The market size of Gastroparesis in 7MM in 2020 was USD 3,219.82 million.


Gastroparesis Emerging Drugs

The emerging drugs of the Gastroparesis market are 


  • Relamorelin
  • Tradipitant
  •  Velusetrag
  • CNSA-001
  • Nimacimab
  • CIN-102
  • TAK 906
  • Metopimazine (NG101)
  • Moventig (Naloxegol)


And many others.  

 

Gastroparesis Key Players

The key players in the Gastroparesis market are


  • Allergan
  • Vanda Pharmaceuticals
  • Theravance Biopharma
  • Censa Pharmaceuticals/PTC Therapeutics
  • Bird Rock Bio
  • CinDome Pharma
  • Takeda
  • Neurogastrx
  • AstraZeneca

And many others. 


Stay tuned for latest updates on Gastroparesis treatment market